ClinicalTrials.gg
CompletedNCT02057172Updated Aug 9, 2016

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

A Phase 2 interventional study of HM11260C and liraglutide in Type 2 Diabetes, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-08-09.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited — 2 open to participants now, 2 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Hanmi Pharmaceutical Company Limited.

Enrollment
2nd of 10
254 · median 102
Started
2014
with 1 other
Phase 2
3 of 10
1 open now
Registered
2nd of 10
by date

Among the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, this one is the 2nd largest by enrollment, is one of 2 that started in 2014, is one of 3 in phase 2, and was the 2nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, or all of them as a file.
02

Study summary

The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • glycaemic control
  • HM11260C
  • placebo
  • safety
  • tolerability
  • type 2 diabetes mellitus
  • efficacy
  • T2DM
  • glycated haemoglobin (HbA1c)
  • glycosylated haemoglobin (HbA1c)
  • Glucagon-Like Peptide-1 (GLP-1) agonists
  • blood sugar levels
  • fasting plasma glucose (FPG)
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages eligible for study : 18 years to 74 years
  • Genders eligible for study : Male and Female
  • Diagnosed with T2DM
  • Received diet and exercise therapy with or without metformin monotherapy
  • levels of between ≥ 7.0% and ≤ 10.0%
  • Females of who are not pregnant and agree to use a reliable method of
  • Written must be obtained

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (lactating) women
  • Diagnosis of type 1 diabetes mellitus
  • Uncontrolled diabetes defined as a FPG level of > 240 mg/dL
  • A significant change in body weight in the 3 months before screening
  • Any history of GI intolerance
  • Personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC
  • Known history of chronic pancreatitis
  • A history of alcohol or drug abuse or drug addiction
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    HM11260C (0.3 mg)

    Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks

    Drug: HM11260C

  • Experimental
    HM11260C (1 mg)

    Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks

    Drug: HM11260C

  • Experimental
    HM11260C (2 mg)

    Weekly administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks

    Drug: HM11260C

  • Experimental
    HM11260C (3 mg)

    Weekly administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks

    Drug: HM11260C

  • Experimental
    HM11260C (4 mg)

    Weekly administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks

    Drug: HM11260C

  • Placebo comparator
    Placebo

    Weekly administration of placebo by subcutaneous injection for 12 weeks

    Drug: Placebo

  • Active comparator
    Liraglutide

    Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.

    Drug: liraglutide

Interventions

  • HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)

    Also known as: LAPS-Exendin-4

  • Liraglutide is a GLP-1 agonist.

    Also known as: Victoza

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks

    Time frame: Up to 127 days

Secondary outcomes

  1. Fasting plasma glucose levels (FPG)

    Time frame: Up to 127 days

  2. 7-point glucose profile

    Time frame: Up to day 127

  3. Other glycaemic control parameters

    Time frame: Up to day 127

  4. Serum lipid profile

    Time frame: Up to day 127

  5. Body weight

    Time frame: Up to day 127

  6. Number of subjects attaining goal glycosylated haemoglobin (HbA1c) <7%

    Time frame: Up to 127 days

Other outcomes

  1. Assess the safety and tolerability of HM11260C

    Time frame: Up to day 127

  2. Assess the immunogenicity of HM11260C

    Time frame: Up to day 127

07

Study locations

1 site
  • Hanmi pharmaceutical
    CA, California, United States
08

References and documents

Publications

  • Rosenstock J, Sorli CH, Trautmann ME, Morales C, Wendisch U, Dailey G, Hompesch M, Choi IY, Kang J, Stewart J, Yoon KH. Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide. Diabetes Care. 2019 Sep;42(9):1733-1741. doi: 10.2337/dc18-2648. Epub 2019 Jul 18. PubMed 31320446 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2014
First posted
Feb 6, 2014
Start
Jan 2014
Primary completionActual
Oct 2014
CompletionActual
Dec 2014
Results delay requested
Aug 8, 2016
Last update
Aug 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02057172
Responsible party
Sponsor
First posted
Feb 6, 2014
Start date
Jan 2014
Primary completion
Oct 2014
Completion
Dec 2014
Last update
Aug 9, 2016

Study contacts

Hanmi Pharmaceutical
study director · clinical4@hanmi.co.kr

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efpeglenatide

Start the discussion